Celldex Therapeutics reports significant progress in Phase 3 trials of barzolvolimab for chronic spontaneous urticaria (CSU), with active enrollment ongoing across 40 countries and 500 sites.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.